# OnCo record nct05903833 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05903833/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05903833", "NCT05903833" ;
  schema:name "Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surge"@en ;
  schema:alternateName "PIERCE"@en ;
  schema:description "A phase 2 trial of Pembrolizumab, Lenvatinib in vulvar cancer, run by AGO Research GmbH, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05903833/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05903833> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2025-06-24" ;
  onco:cancers <https://onco.cc/cancers/vulvar/>, <https://onco.cc/cancers/hpv-associated-vulvar-cancer/>, <https://onco.cc/cancers/hpv-independent-vulvar-cancer/> ;
  onco:technologies <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/lenvatinib/> ;
  onco:companies <https://onco.cc/companies/ago-study-group/> .